Brexpiprazole

• Description:

  Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM) [1][2].

• Product Name Alternative:

  OPC-34712

• UNSPSC:

  12352005

• Hazard Statement:

  H317, H319, H335

• Target:

  5-HT Receptor; Adrenergic Receptor; Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Brexpiprazole.html

• Concentration:

  10mM

• Purity:

  99.80

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles:

  O=C1NC2=C(C=CC(OCCCCN3CCN(C4=C(C=CS5)C5=CC=C4)CC3)=C2)C=C1

• Molecular Formula:

  C25H27N3O2S

• Molecular Weight:

  433.57

• Precautions:

  H317, H319, H335

• References & Citations:

  [1]Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25 (4) :505-11.|[2]Yoshimi N, et al. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25 (3) :356-64.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  5-HT1 Receptor;5-HT2 Receptor; D2 Receptor; mLAG-3; α-1 microglobulin

• CAS Number:

  [913611-97-9]